Bendamustine Plus Rituximab Boost PFS in Indolent Lymphomas Medscape The simple combination of bendamustine plus rituximab (Rituxin) can replace standard therapy in patients newly diagnosed with indolent non-Hodgkin's lymphoma and mantle cell lymphoma, according to a study published online February 20 in the Lancet. Bendamustine data published in The Lancet |
